Mineralys Therapeutics, Inc.
MLYS
$27.38
$0.110.40%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 219.35% | 92.80% | 58.16% | 43.65% | 42.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.01% | -26.05% | -31.57% | 3.49% | 25.69% |
| Operating Income | -2.01% | 26.05% | 31.57% | -3.49% | -25.69% |
| Income Before Tax | 6.80% | 34.14% | 34.45% | -5.51% | -33.97% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 6.80% | 34.14% | 34.45% | -5.51% | -33.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.80% | 34.14% | 34.45% | -5.51% | -33.97% |
| EBIT | -2.01% | 26.05% | 31.57% | -3.49% | -25.69% |
| EBITDA | -2.03% | 26.06% | 31.58% | -3.48% | -25.68% |
| EPS Basic | 40.19% | 59.15% | 53.74% | 20.43% | -13.15% |
| Normalized Basic EPS | 40.19% | 59.15% | 53.74% | 20.45% | -13.13% |
| EPS Diluted | 40.19% | 59.15% | 53.74% | 20.43% | -13.15% |
| Normalized Diluted EPS | 40.19% | 59.15% | 53.74% | 20.45% | -13.13% |
| Average Basic Shares Outstanding | 55.81% | 61.23% | 41.71% | 32.61% | 18.40% |
| Average Diluted Shares Outstanding | 55.81% | 61.23% | 41.71% | 32.61% | 18.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |